Sep 23, 2026 | Press Releases
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the...
Sep 22, 2026 | Press Releases
Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) (“Valion” or the “Company) announced today that it has received formal written...
Sep 1, 2026 | Press Releases
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation...
Aug 27, 2026 | Press Releases
SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) (“Valion Bio” or the “Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding...
Aug 13, 2026 | Press Releases
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod’s First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry begins technical assessment • Regulatory...
Aug 12, 2026 | Press Releases
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned to start this weekNear-Term Program MilestonesStudy...